Senate HELP hearing spotlights delayed FDA front‑of‑package rule and industry influence in obesity crisis

The Senate Health, Education, Labor, and Pensions Committee heard testimony on federal efforts to curb obesity and type 2 diabetes and on a proposed FDA rule for front‑of‑package nutrition labeling.

Chair Bernie Sanders opened the hearing saying more than 35 million Americans have type 2 diabetes and that the American Diabetes Association estimates the annual cost of diabetes in the United States at about $413 billion. He argued that clearer labels and curbs on junk‑food advertising to children are needed to address both health harms and mounting public costs.

"How long does it take to put a bloody label on a product?" Sanders asked, pressing FDA leadership on missed internal deadlines for a front‑of‑package proposal. Sanders noted other countries have implemented warning labels and cited Chile as an example where calories from labeled products dropped after the law took effect.

FDA Commissioner Robert Califf said the agency has prioritized nutrition reforms within a newly reorganized Human Foods Program but described legal and resource limits. "We are not waiting to act where the evidence is clear," Califf said, listing work on front‑of‑package labeling, sodium reduction, and updates to the agency's 'healthy' claim. He warned that changes misunderstood by courts or unsupported by defensible science risk years of delay through litigation.

Deputy Commissioner M. Jones told senators the FDA missed re‑evaluation of certain additives (see separate coverage of dyes) and that the agency has referred a proposed front‑of‑package rule to the Office of Management and Budget; senators faulted the agency for multiple postponed public timelines before that submission.

Senator Bill Cassidy, the committee's ranking member, framed the topic as bipartisan and urged Congress and FDA to coordinate on research, noting the National Institutes of Health has underfunded nutrition and obesity research. Multiple senators emphasized the need for clearer consumer information and for Congress to provide explicit statutory authority if the agency is to take stronger regulatory steps.

The committee requested additional metrics and asked for post‑hearing questions for the record; Chair Sanders set a deadline of Dec. 19 by 5 p.m. for follow‑up questions.

The hearing produced no votes or formal legislative action; it concluded with the committee asking for further information from FDA and continued oversight work on labelling, research coordination, and possible legislative fixes.